Physician

Jose L Mendoza, M.D.

According to 2025 Medicare claims, Jose Mendoza, M.D. (NPI: 1982648036) practices hematology/oncology in the Washington, DC-MD market, with the plurality of this provider's patient population coming from Prince Georges, MD. This provider's primary affiliated billing organization is MARYLAND ONCOLOGY HEMATOLOGY, P.A. (NPI: 1821271032; TIN: 113652573) and primary practice location at 20613-3045.

Mendoza's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,132 traditional Medicare patients, billed 186,900 HCPCS/CPT codes, and received $3,287,796 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,002 prescription claims across 182 beneficiaries totaling $3,832,442 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 82 claims. Open Payments data shows 131 records totaling $35,609. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,621,154 to $3,287,796. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $470,470 to $3,832,442. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	882	155,529	$1,621,154
2016	1,004	196,420	$1,886,407
2017	1,039	229,658	$2,716,026
2018	1,049	268,686	$3,103,142
2019	1,004	311,123	$3,669,051
2020	1,023	356,252	$4,510,285
2021	1,130	424,373	$5,050,592
2022	1,168	386,528	$4,497,300
2023	1,100	263,952	$3,646,508
2024	1,132	186,900	$3,287,796

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	151	573	$470,470
2016	138	692	$924,393
2017	122	620	$956,154
2018	148	738	$1,336,769
2019	130	715	$1,762,909
2020	123	759	$2,257,987
2021	130	758	$2,869,577
2022	127	685	$2,653,638
2023	134	728	$2,685,456
2024	182	1,002	$3,832,442

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	46	$4,522
2016	N/R	32	$13,937
2017	N/R	11	$1,045
2018	N/R	44	$4,672
2019	N/R	29	$2,941
2020	N/R	N/R	N/R
2021	N/R	100	$5,074
2022	N/R	97	$2,017
2023	N/R	66	$5,939
2024	N/R	82	$1,536

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	503	1,059	$113
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	390	532	$77
80053	Blood test, comprehensive group of blood chemicals	584	1,881	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	587	2,379	$8
83615	Lactate dehydrogenase (enzyme) level	358	688	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	56	1,568	$779,143
Revlimid	Lenalidomide	43	1,204	$770,922
Xtandi	Enzalutamide	18	540	$263,705
Jakafi	Ruxolitinib Phosphate	20	600	$263,402
Tasigna	Nilotinib Hcl	13	364	$245,922

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	21	$594
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	24	$426
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	12	$228
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	12	$207
J8520	Capecitabine, oral, 150 mg	N	N/R	13	$81

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	127	$14,217	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	4	$21,392	Celgene Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jose L. Mendoza, M.D.?

Tedicare shows public-source Medicare data for Jose L. Mendoza, M.D. (NPI 1982648036), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jose L. Mendoza, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Jose L. Mendoza, M.D.?

Jose L. Mendoza, M.D. is linked to MARYLAND ONCOLOGY HEMATOLOGY, P.A. (billing NPI 1821271032) in the available physician profile data.

Does Jose L. Mendoza, M.D. have Open Payments data?

Jose L. Mendoza, M.D. has 131 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.